✨ Your Portfolio is fetched and updated from zerodha.
Mid Pharmaceuticals

Aurobindo Pharma Ltd.

AUROPHARMA

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹61,071 Cr.
P/E
18.01

Aurobindo Pharma Ltd.

  • Aurobindo Pharma
  • Alkem Laboratories
  • Glenmark Pharma
  • TJI Pharma
FAQs on Aurobindo Pharma Ltd. Shareprice

Aurobindo Pharma has given lower returns compared to its competitors.
Aurobindo Pharma has grown at ~3.92% over the last 9yrs while peers have grown at a median rate of 9.63%

Aurobindo Pharma is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA.
Latest PE of Aurobindo Pharma is 17.91, while 3 year average PE is 17.13.
Also latest EV/EBITDA of Aurobindo Pharma is 9.25 while 3yr average is 10.25.

View FAQ's On Business
Growth Table
  • Aurobindo Pharma Ltd.
  • Alkem Laboratories
  • Glenmark Pharma
Balance Sheet
  • Aurobindo Pharma Ltd.
  • Alkem Laboratories
  • Glenmark Pharma
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Aurobindo Pharma Ltd.
  • Alkem Laboratories
  • Glenmark Pharma
Cash Flow
  • Aurobindo Pharma Ltd.
  • Alkem Laboratories
  • Glenmark Pharma
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Aurobindo Pharma Ltd.
  • Alkem Laboratories
  • Glenmark Pharma
Quarterly Results
  • Aurobindo Pharma Ltd.
  • Alkem Laboratories
  • Glenmark Pharma
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF
FAQs on Aurobindo Pharma Ltd. Financials

Balance sheet of Aurobindo Pharma is strong.
It shouldn't have solvency or liquidity issues.

The net debt of Aurobindo Pharma is decreasing.
Latest net debt of Aurobindo Pharma is -₹8,529.09 Crs as of Mar-25.
This is less than Mar-24 when it was -₹6,241.12 Crs.

The profit is oscillating.
The profit of Aurobindo Pharma is ₹3,418 Crs for TTM, ₹3,486 Crs for Mar 2025 and ₹3,173 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Aurobindo Pharma latest dividend payout ratio is 8.31% and 3yr average dividend payout ratio is 8.71%

Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech